From promise to people.

At Lineage, our mission is to pioneer a new branch of medicine based on transplanting specific cell types to patients with serious medical conditions

Our
Pipeline

Company
Presentation

Lineage’s partner Genentech has launched a Phase 2a study of RG6501 (OpRegen®) in patients with geographic atrophy secondary to age-related macular degeneration

In the Media

View more media

OPC1 Patient Spotlight

Sonia’s OpRegen Story

News and Events

View more news and events

Nov 10, 2022 – Lineage Cell Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update

Oct 10, 2022 – Lineage Announces Notice of Allowance of Two Patents Covering Processes for Manufacturing Allogeneic Oligodendrocyte Progenitor and Retinal Pigmented Epithelium Cells

Recent Financials

Listen to our 3^rd Quarter 2022
Earnings Call